Portland, OR, United States
Portland, OR, United States

Time filter

Source Type

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Market Research Services Global Market Briefing 2017" report to their offering. 'Market Research Services Global Market Briefing' provides strategists, marketers and senior management with the critical information they need to assess the global market research services. Market research services comprise companies that offers services such as aiding in marketing activities, studying and analyzing the market as per client needs and specifications. The market research services market does not include legal services, accounting, and other major general professional services. For more information about this report visit http://www.researchandmarkets.com/research/jll9f6/market_research


San Francisco, CA, April 27, 2017 --( The release of the new Language Studio™ NMT capabilities, complementing the existing Statistical Machine Translation (SMT) capabilities in the LexisNexis IP Solutions current workflow, provides for more accurate machine translations of IP documents. LexisNexis is once again asserting its market leadership position by offering the most innovative technologies and solutions available today to provide customers with industry leading Intellectual Property tools. “We have always pioneered advanced solutions to enhance our offerings, and our deployment of the new Language Studio™ NMT capabilities extends our existing partnership with Omniscien Technologies,” says Eric van Stegeren, Senior Director Technical Solutions and Managing Director of LexisNexis IP Solutions. “It provides us with the ability once again to establish our leadership position in the industry and provide a unique, high-quality offering to our clients,” van Stegeren continued. “Language Studio™ from Omniscien Technologies has served us well over the years, and the addition of NMT allows us the flexibility to select the best technology for the job dynamically, be it SMT, NMT or a combination of both. This represents a unique opportunity to achieve far better quality translations and solutions as part of our products,” says Laura Rossi, Manager Language Technology Solutions at LexisNexis IP Solutions. “We are truly honored and thrilled by the opportunity to be able to continue and extend our long-standing relationship with LexisNexis IP Solutions. Taking such a sophisticated new technology to market in an environment with such complexity as Intellectual Property data and the associated volumes of more than 100 billion words this year alone, requires a highly skilled team on both sides of the partnership as well as the effective collaboration which we have found in LexisNexis IP Solutions,” says Andrew Rufener, CEO of Omniscien Technologies. This collaboration between LexisNexis IP Solutions and Omniscien Technologies marks the largest commercial NMT deployment for intellectual property data translation between Asian and European languages in the world. Language Studio™ with Neural Machine Translation was announced for general availability on April 21 and is available to the global customer base of Omniscien Technologies in Language Studio™ Cloud as well as Language Studio™ Enterprise as an on-premise solution for customers requiring secure or high-volume installations. LexisNexis IP Solutions is part of LexisNexis® Legal & Professional. About LexisNexis® Legal & Professional LexisNexis Legal & Professional is a leading global provider of content and technology solutions that enable professionals in legal, corporate, tax, government, academic and non-profit organizations to make informed decisions and achieve better business outcomes. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. Today, LexisNexis Legal & Professional harnesses leading-edge technology and world-class content to help professionals work in faster, easier and more effective ways. Through close collaboration with its customers, the company ensures organizations can leverage its solutions to reduce risk, improve productivity, increase profitability and grow their business. LexisNexis Legal & Professional, which serves customers in more than 175 countries with 10,000 employees worldwide, is part of RELX Group, a global provider of information and analytics for professional and business customers across industries. About Omniscien Technologies Omniscien Technologies is a leading global supplier of high-performance and secure high-quality Language Processing, Machine Translation (MT) and Machine Learning technologies and services for content intensive applications. Our wide range of solutions serves clientele from various industries including the Localization Industry, Online Research Services, Publishing, eCommerce, Media, Online Travel, Technology, Enterprise and Government. Omniscien Technologies has gained a reputation for cutting edge solutions with its Language Studio™ platform. Depending upon the customer’s unique requirements, Language Studio™ can be deployed in a variety of ways to integrate with their in-house data processing and translation management systems, and it offers unparalleled levels of customization and control as well as feature rich pre- and post-processing, enabling customers with even the most complex data to achieve both high quality and high volume output to satisfy every use case. Omniscien Technologies has by far the most comprehensive and feature rich system in the market today. Covering 548 language pairs and with a number of industry specific solutions, Omniscien Technologies remains the partner of choice for customers with complex, high-volume bespoke data processing and machine translation needs. San Francisco, CA, April 27, 2017 --( PR.com )-- Omniscien Technologies (formerly Asia Online) today announced a partnership with LexisNexis to deploy Language Studio™ Neural Machine Translation (NMT) to further support the LexisNexis intellectual property workflow. This agreement offers the marketplace a superior customized solution based on the combination of expertise from leaders in machine translation and intellectual property solutions, Omniscien Technologies and LexisNexis IP.The release of the new Language Studio™ NMT capabilities, complementing the existing Statistical Machine Translation (SMT) capabilities in the LexisNexis IP Solutions current workflow, provides for more accurate machine translations of IP documents. LexisNexis is once again asserting its market leadership position by offering the most innovative technologies and solutions available today to provide customers with industry leading Intellectual Property tools.“We have always pioneered advanced solutions to enhance our offerings, and our deployment of the new Language Studio™ NMT capabilities extends our existing partnership with Omniscien Technologies,” says Eric van Stegeren, Senior Director Technical Solutions and Managing Director of LexisNexis IP Solutions. “It provides us with the ability once again to establish our leadership position in the industry and provide a unique, high-quality offering to our clients,” van Stegeren continued.“Language Studio™ from Omniscien Technologies has served us well over the years, and the addition of NMT allows us the flexibility to select the best technology for the job dynamically, be it SMT, NMT or a combination of both. This represents a unique opportunity to achieve far better quality translations and solutions as part of our products,” says Laura Rossi, Manager Language Technology Solutions at LexisNexis IP Solutions.“We are truly honored and thrilled by the opportunity to be able to continue and extend our long-standing relationship with LexisNexis IP Solutions. Taking such a sophisticated new technology to market in an environment with such complexity as Intellectual Property data and the associated volumes of more than 100 billion words this year alone, requires a highly skilled team on both sides of the partnership as well as the effective collaboration which we have found in LexisNexis IP Solutions,” says Andrew Rufener, CEO of Omniscien Technologies.This collaboration between LexisNexis IP Solutions and Omniscien Technologies marks the largest commercial NMT deployment for intellectual property data translation between Asian and European languages in the world.Language Studio™ with Neural Machine Translation was announced for general availability on April 21 and is available to the global customer base of Omniscien Technologies in Language Studio™ Cloud as well as Language Studio™ Enterprise as an on-premise solution for customers requiring secure or high-volume installations.LexisNexis IP Solutions is part of LexisNexis® Legal & Professional.About LexisNexis® Legal & ProfessionalLexisNexis Legal & Professional is a leading global provider of content and technology solutions that enable professionals in legal, corporate, tax, government, academic and non-profit organizations to make informed decisions and achieve better business outcomes. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. Today, LexisNexis Legal & Professional harnesses leading-edge technology and world-class content to help professionals work in faster, easier and more effective ways. Through close collaboration with its customers, the company ensures organizations can leverage its solutions to reduce risk, improve productivity, increase profitability and grow their business. LexisNexis Legal & Professional, which serves customers in more than 175 countries with 10,000 employees worldwide, is part of RELX Group, a global provider of information and analytics for professional and business customers across industries.About Omniscien TechnologiesOmniscien Technologies is a leading global supplier of high-performance and secure high-quality Language Processing, Machine Translation (MT) and Machine Learning technologies and services for content intensive applications. Our wide range of solutions serves clientele from various industries including the Localization Industry, Online Research Services, Publishing, eCommerce, Media, Online Travel, Technology, Enterprise and Government.Omniscien Technologies has gained a reputation for cutting edge solutions with its Language Studio™ platform. Depending upon the customer’s unique requirements, Language Studio™ can be deployed in a variety of ways to integrate with their in-house data processing and translation management systems, and it offers unparalleled levels of customization and control as well as feature rich pre- and post-processing, enabling customers with even the most complex data to achieve both high quality and high volume output to satisfy every use case. Omniscien Technologies has by far the most comprehensive and feature rich system in the market today.Covering 548 language pairs and with a number of industry specific solutions, Omniscien Technologies remains the partner of choice for customers with complex, high-volume bespoke data processing and machine translation needs. Click here to view the list of recent Press Releases from Omniscien Technologies


News Article | March 1, 2017
Site: www.prweb.com

Mercator Advisory Group’s most recent research report, Mobile Payments Platforms and Markets: How High Is Up?, presents a framework for the assessing the U.S. mobile payments market. The report describes the current market landscape and discusses future implications for payments technology vendors, developers, merchants, and consumers. With e-commerce activity becoming the growth engine for U.S. retail sales, mobile payments technology and applications are expanding at a rapid clip to cash in on increasing consumer purchase transactions made via mobile browsers and smartphone apps. Competition is intensifying among financial institutions, card networks, and alternative payment vendors seeking to grab their share of mobile payments transactions, now available to both online and in-store shoppers. While the smartphone makers were first to market with the mobile apps Apple Pay, Android Pay, Samsung Pay, financial institutions and card networks have joined with their own entries into the mobile payment universe such as Chase Pay and Citi Pay. Not to be left behind, single merchants, led by nationwide chains and franchises such as Starbucks and Dunkin’ Donuts are launching their own mobile apps with special features to meet the needs of their customer bases. Despite early optimism that mobile payment adoption would be widespread among both merchants and consumers, various inhibiting factors are in play. Challenges to higher mobile payment utilization include systems complexity and consumers’ concerns about the security of the mobile payment method. Some emerging technologies are arriving that can address the mobile pay challenges making transactions more seamless and easier to use. This Mercator Advisory Group research report delves into the current state of mobile payments and discusses implications and areas of opportunity for technology developers, financial vendors, and merchants. “Mobile shoppers want more integrated features and need more engaging reasons to use mobile payments, but most payment vendors and their merchant clients have simply not yet provided that,” comments Raymond Pucci, Associate Director of Research Services at Mercator Advisory Group, author of the report. This research report contains 26 pages and 11 exhibits. Companies mentioned in this report include: Amazon, Apple, Capital One, Chase Bank, Chipotle, Citibank, Cybersource, CVS Health, Discover, Domino’s, Dunkin’ Donuts, EMVCo, Facebook, FIS Global, Google, Groupon, GrubHub, Kohl’s, Lyft, MasterCard, OpenTable, PayPal, Samsung, Starbucks, Square, Target, Uber, Visa, Walgreens, Walmart, and Whole Foods. Members of Mercator Advisory Group’s Emerging Technology Service have access to this report as well as the upcoming research for the year ahead, presentations, analyst access, and other membership benefits. For more information and media inquiries, please call Mercator Advisory Group's main line: (781) 419-1700, send email to media(at)mercatoradvisorygroup(dot)com. For free industry news, opinions, research, company information and more visit us at http://www.PaymentsJournal.com. About Mercator Advisory Group Mercator Advisory Group is the leading independent research and advisory services firm exclusively focused on the payments and banking industries. We deliver pragmatic and timely research and advice designed to help our clients uncover the most lucrative opportunities to maximize revenue growth and contain costs. Our clients range from the world's largest payment issuers, acquirers, processors, merchants and associations to leading technology providers and investors. Mercator Advisory Group is also the publisher of the online payments and banking news and information portal PaymentsJournal.com.


The report, "Nanotechnology Market By Type (Nanocomposites, Nanofibers, Nanoceramics, Nanomagnetics); By Application (Medical diagnosis, Energy, ICT, Nano-EHS); By End-Users (Electronics, Pharmaceuticals, Biotechnology, Textile, Military) - Forecast (2016-2021)", published by IndustryARC, the global nanotechnology market revenue is forecast to grow at 16.9% CAGR to reach $12.83 Billion by 2021. Browse 18 Market Tables, 66 Figures spread through 179 Pages and an in-depth TOC on "Nanotechnology Market (2016 - 2021)" http://industryarc.com/Report/15022/nanotechnology-market.html Nanotechnology has the potential to solve problems related to human civilizations, pertaining to both basic needs and aspirations for a comfortable life. Even though nanotechnology involves the manipulation of matter on an atomic, molecular and supramolecular scale, the particular technological goal is of precisely manipulating atoms and molecules for fabrication of macro scale products, also now referred to as molecular nanotechnology. Nanotechnology is evolving towards becoming a general-purpose technology by 2020, encompassing four generations of products with increasing structural and dynamic complexity: Huge expectation from the society: By knowing the advantages and benefits of nanotechnology, people are waiting for the breakthrough of nanotechnology products in all areas of the consumer requirements in the society. Opportunity for new innovative product development: Based on substantial advantages and hence expected huge demand for nanotech products, there are infinite opportunities for new product development in different areas of the society. Opportunity for both small business and mega business players based on their investment capacity: Since nanotechnology products vary from simple cosmetic product to screen infrared rays from skin to artificial food products to self-generating molecular motors, depending on the interest and capability of firm, it can focus on a particular type of product so that both small and financially strong business firms have opportunity in nanotechnology product development and marketing. Opportunity for new product development for entrepreneurs in their existing field itself so that they can use their experience: Being general purpose technology, nanotechnology provides scope for existing firms to upgrade their products/services. Hence, the existing entrepreneurs can plan to improve their products by improving them using nanotechnology features for improved performance. The new discoveries and innovations get patent protection to commercialize their inventions, so that the investment of the firms will not be wasted due to their right to get patent protection for their inventions. The new technology gives an opportunity to explore new business and sustainable earnings through the use of systematic commercialization process. New inventions based on new technology, usually attract attention due to their ingenuity, but a product must also be useful and compelling, enabling it to be used in everyday life. The objective of the firm is to identify a market for its new products. From a business perspective, the steps to be followed for the successful commercialization of a nanotechnology based product include market size, market potential, and the economic scenario of the countries and the people who use such products. Common challenges faced by nanotechnology firms are: Time Lag: The average time delay between research, completion, and commercialization of a nanotechnology product can lie between three to five years. The banks and other financial funding agencies, find this time lag to be a major detriment due to the fact of the block of their capital. Valley of Death: This is the gap between a positive scientific result of a researcher and obtaining supporting funds for commercialization and prototyping of the product. Since the cost of commercialization is very high compared to the invention cost of the product, usually, the scientist who invented the product may not have the interest in commercialization, but the firms invested for such research have to spend to en-cash its business opportunity. Lack of infrastructure: Nanotechnology product based research is expensive and requires costly instruments. The lack of infrastructure retards the progress of new product invention. Lack of standard for evaluation: A major obstacle for developing Nano-products is the lack of standards for evaluation of performance at different stages of research. Because of this, normalizing standards by which nanotechnologies can be evaluated are lacking which affects the patenting process. Bureaucratic delays: Patent policies take up to thirty-six months to respond to a single application, a serious problem when even a slight delay can be detrimental. Due to lack of a coherent policy on technology transfer from universities to start-up businesses and a considerable red tape must be dealt with for any such transfer using black ocean strategy. Dearth of funding: Since the research in nanotechnology is capital intensive due to the state-of-the-art instruments requirement, firms face challenges in obtaining funding. Thus, commercialization of nanotechnology products requires huge investments which small to medium firms cannot secure easily. Lack of trained professionals: The lack of sufficiently trained scientists, engineers, technicians, and researchers in the field is another barrier. This is mostly due to lack of addition of Nano science and technology in the engineering and science syllabus. Sustainability in the market: The final challenge for the firms is maintaining the sustainability for the commercialized product or service for longer time to get the return on investment and expected profits through planning and executing proper marketing strategies. Carbon nanotubes (CNTs) have recently emerged as one of the most important classes of nano materials having enormous potential to spark off the next industrial revolution. CNTs' unique and extraordinary properties such as extremely high electrical and thermal conductivities make it an ideal candidate for electronic devices. This product falls under the Nano composites market segment, which is anticipated to grow at a CAGR of 16.6% during the forecast period between 2016 and 2021. Europe accounted for 33% market share in global nanotechnology market revenue in 2015 after Americas region and is forecast to grow at a CAGR of 15.6% to reach $3.98 billion by 2021. APAC region is projected to grow at a rate of 20.9% CAGR during the forecast period 2016-2021. On aggregate, the global nanotechnology market revenue is forecast to grow at 16.9% CAGR to reach $12.83 billion by 2021. Nano composites dominate the market with a share of 65% and generating revenues of $2.92 billion in 2015. It is forecast to grow at a CAGR of 16.6% to reach $8.17 billion by 2021, which is mainly attributed to the growing demand from the end user segments. Increasing emphasis on renewable and sustainable energy sector with the use of low cost materials fuels the growth of nanotechnology market in the energy and environment sectors. Growing demand for efficient and cost-effective healthcare treatment and diagnostics is yet another driver which propels the adoption of Nano-materials in drug delivery and medical devices sector The major areas of nanotechnology research include nanoscale science, development of nanoscale materials as well as modeling of nanoscale devices, materials and interactions. Potential nanotech markets tend to arise from the telecom and information technology industries. Moreover, research activities in the electronics and semiconductor industry as well as pharmaceuticals industry will also account for a significant market share of the global nanotechnology market in the upcoming years. Sizeable investments in the nanotechnology companies would foster the development of new products and processes. Following are few key players profiled in this report as part of the market landscape analysis: Ablynx NV Nanophase Technologies Corporation, Acusphere Inc., Altair Nanotechnologies Inc., Carbon Nanotechnologies Inc., Evident Thermoelectrics, Glonatech S.A., Isotron Corporation, Luna Innovations Incorporated, Molecular Manufacturing Enterprises Incorporated, Moore Nanotechnology Systems,LLC, Nanometrics Inc., Nanophase Technologies Corporation, Nanoscale Corporation, Nanosys Inc., Nanoworld AG Oxford Instruments PLC, Particular GmbH, PEN Inc., SouthWest Nano Technologies Inc., Unidym Inc., Zyvex Technologies Corporation NanoInk,Inc & many more. The market has also been analyzed for four geographic regions which include North America, APAC, Europe and Rest of the World. Nanowire Battery Market: By Applications (Energy Generation, Consumer Products, Controllers and others); By Nanowire Type (Metallic, Semiconducting, Insulating, Molecular); By Region - Forecast (2015-2020) http://industryarc.com/Report/15094/nanowire-battery-market.html Nanocellulose Market: By Type (Cellulose Nanocrystals, Cellulose Nanofibrils, Bacterial Cellulose); By Applications (Paperboard And Plastics, Food Packaging, Pharmaceutical, Biomedical, Paints, Coatings, Water-treatment, Others)-Forecast (2015 - 2020) http://industryarc.com/Report/11681/nanocellulose-market-analysis.html IndustryARC is a research and consulting firm that publishes more than 500 reports annually in various industries, such as Aerospace & Defense, Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare. IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights on the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business. We look forward to support the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today. Media Contact Mr. Sanjay Matthews Business Development Manager Email: sales@industryarc.com Contact Sales: 1-614-588-8538 (Ext-101) Connect with us on LinkedIn - https://www.linkedin.com/company/industryarc IndustryARC at #GWF2017 - http://industryarc.com/Article/7697/iarc-ceo-speaking-at-geospatial-world-forum-2017.html


ATLANTA--(BUSINESS WIRE)--Navicure®, a provider of cloud-based healthcare claims management, patient payment and data analytics solutions, announced findings from its first Patient Payment Check-Up™. Conducted by HIMSS Analytics and fielded in January 2017, the company’s national survey reveals key differences in attitudes and behavior between those billing for healthcare and those paying for it. “Our study indicates strong patient interest in more convenient ways to understand and pay their bills. Ironically, patient demand is ahead of current hospital and practice adoption,” said Jim Denny, founder, president and CEO of Navicure. “A new generation of tools are available to improve patient satisfaction and allow healthcare organizations to collect more, faster, and at less cost. The return on investment is phenomenal. We’re seeing a lot of interest in our patient payment solutions, especially among organizations with a high and growing percentage of patient revenue.” “When compared to provider expectations and behaviors, the percentage of patients seeking technology-based payment options via email, e-statements and automated payment plans is indicative of healthcare consumerism’s significant influence,” said Bryan Fiekers, Sr. Director, Research Services, HIMSS Analytics. Join Bryan Fiekers and Phil Dolan, Chief Marketing Officer, Navicure, for a co-presentation of the 2017 Patient Payment Check-Up introductory findings during HIMSS17, in Orlando, FL. The presentation will be held on Monday, Feb. 20 at the HIMSS Analytics booth (#2133) from 3:30-4 p.m. EST. The discussion will also be live-streamed via Facebook Live on Navicure’s Facebook page, https://www.facebook.com/navicure. Full survey findings and the corresponding report will be made available later this year. Deployed as a combination of two quantitative surveys, research assessed both patients and providers. Navicure is a provider of cloud-based healthcare claims management and patient payment solutions that enable healthcare organizations of all sizes to increase revenue, accelerate cash flow, and reduce the cost and effort of managing insurance claims, patient billing and payments, and data analytics. Serving more than 100,000 healthcare providers nationwide, Navicure’s complete healthcare revenue cycle management platform, Navicure® Total RCM Platform™, integrates payer and patient billing with an advanced analytics dashboard utilizing real-time data to continually optimize operational workflow and financial results. Navicure’s unique 3-Ring® service supports every client with trained, experienced analysts who guarantee that every call will be answered within three rings. Navicure is the exclusive claims management and patient payment solution of the MGMA Executive Partner network. The company received the 2017 Best in KLAS® ranking for the claims and clearinghouse (over 20 physician) segment. Navicure was also the top-ranked end-to-end revenue cycle leader in three categories as part of the 2016 Black Book™ RCM Survey. For more information, please visit www.navicure.com, or follow @Navicure on Twitter. HIMSS Analytics® is a global healthcare IT market intelligence, research and standards organization assisting clientele in both healthcare delivery and healthcare technology solutions business development to make lasting improvements in efficiency and performance. HIMSS Analytics offers a wide array of market insight and research solutions custom-created to meet clientele business objectives. Offering a full spectrum of research services from general market understanding and opportunities, to finding ways to improve business effectiveness, HIMSS Analytics’ team of experienced analysts and thought leaders guide clients through the fast-paced, highly competitive health IT market to better performance.


News Article | February 27, 2017
Site: www.accesswire.com

LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces its post-earnings coverage on Myriad Genetics, Inc. (NASDAQ: MYGN). The Company released its second quarter fiscal 2017 (Q2 FY17) results on February 07, 2017. The Salt Lake City-based Company's total revenues reported a 2% y-o-y growth, outperforming market consensus estimates. Register with us now for your free membership at: One of Myriad Genetics' competitors within the Research Services space, INC Research Holdings, Inc. (NASDAQ: INCR), announced on February 06, 2017, that it will release its Q4 and full year 2016 financial results on Tuesday, February 28, 2017, prior to its quarterly earnings call at 8:00 a.m. ET. AWS will be initiating a research report on INC Research in the coming days. Today, AWS is promoting its earnings coverage on MYGN; touching on INCR. Get our free coverage by signing up to: In Q2 FY17, Myriad reported total revenues of $196.5 million, which came in above the $193.3 million reported in the year-ago same period. Total revenues numbers for the reported quarter beat market consensus estimates of $191 million. The year-over-year rise in the Company's top-line was primarily due to sequential growth in hereditary cancer revenues and strong GeneSight results. The molecular diagnostic Company posted GAAP net income of $5.9 million, or $0.09 per diluted share, in Q2 FY17 compared to $37.1 million, or $0.50 per diluted share, reported in Q2 FY16. The Company's Q2 FY17 non-GAAP net income stood at $17.5 million, or $0.26 per diluted share, compared to $33.5 million, or $0.45 per diluted share, in the previous year's comparable quarter. Wall Street had expected the Company to report non-GAAP net income of $0.24 per diluted share. During Q2 FY17, Myriad's gross profit came in at $152.1 million compared to $152.7 million in the prior year's same quarter. However, the Company's gross margin fell to 77.4% in Q2 FY17 from 79.0% in the year ago comparable quarter. The Company's operating expenses increased to $138.9 million in Q2 FY17 from $107.5 million in Q2 FY16. Moreover, the Company's operating income declined 71% during Q2 FY17 to $13.2 million from $45.2 million in Q2 FY16. The Company's operating margin also fell to 6.7% of total revenues in Q2 FY17 from 23.4% of total revenues in the previous year's corresponding quarter. In the reported quarter, non-GAAP operating income declined to $23.6 million, or 12.0% of total revenues, from $48.4 million, or 25.0% of total revenues, in the previous year's same quarter. During Q2 FY17, Molecular diagnostic tests reported total revenue of $183.9 million, up 1% from $182.6 million in Q2 FY16, primarily due to a 78% surged in EndoPredict testing revenues to $1.6 million and Prolaris testing revenues, which rose 63% to $3.1 million. However, in Q2 FY17, Hereditary cancer testing revenues fell 13% y-o-y to $143.9 million, Vectra DA testing revenues was down by 5% to $10.7 million, while other testing revenues remained flat at $2.9 million. Furthermore, the segment's GeneSight testing revenue during the reported quarter stood at $21.7 million. Additionally, Pharmaceutical and clinical service segment's revenues rose 18% y-o-y during Q2 FY17 to $12.6 million. During Q2 FY17, Myriad reported GAAP cash flow from operations of $31.4 million compared to $40.9 million in the prior year's comparable period. Furthermore, free cash flow during the reported quarter was $29.0 million versus $39.8 million in Q2 FY16. As on December 31, 2016, the Company had cash and cash equivalents balance of $108.1 million, compared to $68.5 million in as on June 30, 2016. Furthermore, the Company reported long-term debt balance of $204.0 million as on December 31, 2016. During Q2 FY17, the Company bought back approximately 600,000 shares of its common stock, for $10 million and ended the quarter with approximately $161 million remaining under its share repurchase program. In its guidance for Q3 FY17, Myriad's management expects revenues to be between $188 million and $190 million. For Q3 FY17, GAAP diluted EPS is projected to be in the range of $0.08 to $0.10, while adjusted EPS for the same period is forecasted to be in the range of $0.23 to $0.25. For full year FY17, the Company anticipates revenue range of $745 million to $755 million. Additionally, GAAP diluted EPS for FY17 is forecasted to be between $0.31 and $0.36; whereas full year adjusted EPS is estimated to be in the range of $1.00 to $1.05. Myriad Genetics At the closing bell, on Friday, February 24, 2017, MYGN's stock slightly slipped 0.37%, ending the trading session at $18.98. A total volume of 1.67 million shares were traded at the end of the day, which was higher than the 3-month average volume of 1.51 million shares. In the last month and previous three months, shares of the Company have surged 17.23% and 11.32%, respectively. Moreover, the stock rallied 13.86% since the start of the year. Shares of the company have a PE ratio of 19.08 and have a market capitalization of $1.30 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | February 27, 2017
Site: marketersmedia.com

LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces its post-earnings coverage on Myriad Genetics, Inc. (NASDAQ: MYGN). The Company released its second quarter fiscal 2017 (Q2 FY17) results on February 07, 2017. The Salt Lake City-based Company's total revenues reported a 2% y-o-y growth, outperforming market consensus estimates. Register with us now for your free membership at: One of Myriad Genetics' competitors within the Research Services space, INC Research Holdings, Inc. (NASDAQ: INCR), announced on February 06, 2017, that it will release its Q4 and full year 2016 financial results on Tuesday, February 28, 2017, prior to its quarterly earnings call at 8:00 a.m. ET. AWS will be initiating a research report on INC Research in the coming days. Today, AWS is promoting its earnings coverage on MYGN; touching on INCR. Get our free coverage by signing up to: In Q2 FY17, Myriad reported total revenues of $196.5 million, which came in above the $193.3 million reported in the year-ago same period. Total revenues numbers for the reported quarter beat market consensus estimates of $191 million. The year-over-year rise in the Company's top-line was primarily due to sequential growth in hereditary cancer revenues and strong GeneSight results. The molecular diagnostic Company posted GAAP net income of $5.9 million, or $0.09 per diluted share, in Q2 FY17 compared to $37.1 million, or $0.50 per diluted share, reported in Q2 FY16. The Company's Q2 FY17 non-GAAP net income stood at $17.5 million, or $0.26 per diluted share, compared to $33.5 million, or $0.45 per diluted share, in the previous year's comparable quarter. Wall Street had expected the Company to report non-GAAP net income of $0.24 per diluted share. During Q2 FY17, Myriad's gross profit came in at $152.1 million compared to $152.7 million in the prior year's same quarter. However, the Company's gross margin fell to 77.4% in Q2 FY17 from 79.0% in the year ago comparable quarter. The Company's operating expenses increased to $138.9 million in Q2 FY17 from $107.5 million in Q2 FY16. Moreover, the Company's operating income declined 71% during Q2 FY17 to $13.2 million from $45.2 million in Q2 FY16. The Company's operating margin also fell to 6.7% of total revenues in Q2 FY17 from 23.4% of total revenues in the previous year's corresponding quarter. In the reported quarter, non-GAAP operating income declined to $23.6 million, or 12.0% of total revenues, from $48.4 million, or 25.0% of total revenues, in the previous year's same quarter. During Q2 FY17, Molecular diagnostic tests reported total revenue of $183.9 million, up 1% from $182.6 million in Q2 FY16, primarily due to a 78% surged in EndoPredict testing revenues to $1.6 million and Prolaris testing revenues, which rose 63% to $3.1 million. However, in Q2 FY17, Hereditary cancer testing revenues fell 13% y-o-y to $143.9 million, Vectra DA testing revenues was down by 5% to $10.7 million, while other testing revenues remained flat at $2.9 million. Furthermore, the segment's GeneSight testing revenue during the reported quarter stood at $21.7 million. Additionally, Pharmaceutical and clinical service segment's revenues rose 18% y-o-y during Q2 FY17 to $12.6 million. During Q2 FY17, Myriad reported GAAP cash flow from operations of $31.4 million compared to $40.9 million in the prior year's comparable period. Furthermore, free cash flow during the reported quarter was $29.0 million versus $39.8 million in Q2 FY16. As on December 31, 2016, the Company had cash and cash equivalents balance of $108.1 million, compared to $68.5 million in as on June 30, 2016. Furthermore, the Company reported long-term debt balance of $204.0 million as on December 31, 2016. During Q2 FY17, the Company bought back approximately 600,000 shares of its common stock, for $10 million and ended the quarter with approximately $161 million remaining under its share repurchase program. In its guidance for Q3 FY17, Myriad's management expects revenues to be between $188 million and $190 million. For Q3 FY17, GAAP diluted EPS is projected to be in the range of $0.08 to $0.10, while adjusted EPS for the same period is forecasted to be in the range of $0.23 to $0.25. For full year FY17, the Company anticipates revenue range of $745 million to $755 million. Additionally, GAAP diluted EPS for FY17 is forecasted to be between $0.31 and $0.36; whereas full year adjusted EPS is estimated to be in the range of $1.00 to $1.05. Myriad Genetics At the closing bell, on Friday, February 24, 2017, MYGN's stock slightly slipped 0.37%, ending the trading session at $18.98. A total volume of 1.67 million shares were traded at the end of the day, which was higher than the 3-month average volume of 1.51 million shares. In the last month and previous three months, shares of the Company have surged 17.23% and 11.32%, respectively. Moreover, the stock rallied 13.86% since the start of the year. Shares of the company have a PE ratio of 19.08 and have a market capitalization of $1.30 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces its post-earnings coverage on Myriad Genetics, Inc. (NASDAQ: MYGN). The Company released its second quarter fiscal 2017 (Q2 FY17) results on February 07, 2017. The Salt Lake City-based Company's total revenues reported a 2% y-o-y growth, outperforming market consensus estimates. Register with us now for your free membership at: One of Myriad Genetics' competitors within the Research Services space, INC Research Holdings, Inc. (NASDAQ: INCR), announced on February 06, 2017, that it will release its Q4 and full year 2016 financial results on Tuesday, February 28, 2017, prior to its quarterly earnings call at 8:00 a.m. ET. AWS will be initiating a research report on INC Research in the coming days. Today, AWS is promoting its earnings coverage on MYGN; touching on INCR. Get our free coverage by signing up to: In Q2 FY17, Myriad reported total revenues of $196.5 million, which came in above the $193.3 million reported in the year-ago same period. Total revenues numbers for the reported quarter beat market consensus estimates of $191 million. The year-over-year rise in the Company's top-line was primarily due to sequential growth in hereditary cancer revenues and strong GeneSight results. The molecular diagnostic Company posted GAAP net income of $5.9 million, or $0.09 per diluted share, in Q2 FY17 compared to $37.1 million, or $0.50 per diluted share, reported in Q2 FY16. The Company's Q2 FY17 non-GAAP net income stood at $17.5 million, or $0.26 per diluted share, compared to $33.5 million, or $0.45 per diluted share, in the previous year's comparable quarter. Wall Street had expected the Company to report non-GAAP net income of $0.24 per diluted share. During Q2 FY17, Myriad's gross profit came in at $152.1 million compared to $152.7 million in the prior year's same quarter. However, the Company's gross margin fell to 77.4% in Q2 FY17 from 79.0% in the year ago comparable quarter. The Company's operating expenses increased to $138.9 million in Q2 FY17 from $107.5 million in Q2 FY16. Moreover, the Company's operating income declined 71% during Q2 FY17 to $13.2 million from $45.2 million in Q2 FY16. The Company's operating margin also fell to 6.7% of total revenues in Q2 FY17 from 23.4% of total revenues in the previous year's corresponding quarter. In the reported quarter, non-GAAP operating income declined to $23.6 million, or 12.0% of total revenues, from $48.4 million, or 25.0% of total revenues, in the previous year's same quarter. During Q2 FY17, Molecular diagnostic tests reported total revenue of $183.9 million, up 1% from $182.6 million in Q2 FY16, primarily due to a 78% surged in EndoPredict testing revenues to $1.6 million and Prolaris testing revenues, which rose 63% to $3.1 million. However, in Q2 FY17, Hereditary cancer testing revenues fell 13% y-o-y to $143.9 million, Vectra DA testing revenues was down by 5% to $10.7 million, while other testing revenues remained flat at $2.9 million. Furthermore, the segment's GeneSight testing revenue during the reported quarter stood at $21.7 million. Additionally, Pharmaceutical and clinical service segment's revenues rose 18% y-o-y during Q2 FY17 to $12.6 million. During Q2 FY17, Myriad reported GAAP cash flow from operations of $31.4 million compared to $40.9 million in the prior year's comparable period. Furthermore, free cash flow during the reported quarter was $29.0 million versus $39.8 million in Q2 FY16. As on December 31, 2016, the Company had cash and cash equivalents balance of $108.1 million, compared to $68.5 million in as on June 30, 2016. Furthermore, the Company reported long-term debt balance of $204.0 million as on December 31, 2016. During Q2 FY17, the Company bought back approximately 600,000 shares of its common stock, for $10 million and ended the quarter with approximately $161 million remaining under its share repurchase program. In its guidance for Q3 FY17, Myriad's management expects revenues to be between $188 million and $190 million. For Q3 FY17, GAAP diluted EPS is projected to be in the range of $0.08 to $0.10, while adjusted EPS for the same period is forecasted to be in the range of $0.23 to $0.25. For full year FY17, the Company anticipates revenue range of $745 million to $755 million. Additionally, GAAP diluted EPS for FY17 is forecasted to be between $0.31 and $0.36; whereas full year adjusted EPS is estimated to be in the range of $1.00 to $1.05. Myriad Genetics At the closing bell, on Friday, February 24, 2017, MYGN's stock slightly slipped 0.37%, ending the trading session at $18.98. A total volume of 1.67 million shares were traded at the end of the day, which was higher than the 3-month average volume of 1.51 million shares. In the last month and previous three months, shares of the Company have surged 17.23% and 11.32%, respectively. Moreover, the stock rallied 13.86% since the start of the year. Shares of the company have a PE ratio of 19.08 and have a market capitalization of $1.30 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | February 28, 2017
Site: www.prnewswire.co.uk

TV Has Opportunity to Take Back Central Role in the Home by Offering Smart Home Features BOSTON, Feb. 28, 2017 /PRNewswire/ -- A new report from the User Experience Strategies (USX) group at Strategy Analytics (www.strategyanalytics.com) has explored purchase priorities for a consumer's next TV purchase and next gen TV features. While Screen quality, size, and reliability/reputation are the three main purchasing factors for a new TV, consumers also desire a variety of different options to control it. Next generation TV feature interests include the ability to control and monitor smart home appliances. Surveying consumers in the US, nearly all respondents included in this study indicated better quality as their number one driver for purchasing a new TV, considering it more important than price. Furthermore the majority of respondents also indicated that they plan to purchase a TV that is bigger than the one they currently own; meaning consumers plan to buy bigger as well as better. Features available, methods to control the TV and ease of navigation are also important aspects for consumers to be fully satisfied with their purchase decision. Taryn Tulay, Senior Analyst and report author commented, "Incorporating interactive features and apps on the TV require a variety of control methods to ensure ease of navigation and interaction. The different methods of control should include voice and gesture control, smartphone/tablet control, and most importantly, a dedicated remote." Continued Tulay, "It is imperative that this remote offers quick access to content of interest, and evolves beyond current cumbersome remotes to include: a touchscreen/touchpad remote for effortless and fluid navigation, fewer buttons, keyboard (on touchscreen), customizable buttons, voice control, a chargeable battery and a wireless charging station." Chris Schreiner, Director Syndicated Research Services, UXIP, added, "The TV has the opportunity to take back its central role in the home by offering new features and apps beyond passive media apps. Interactive features such as smart home control provides new use cases for the big screen. Such a feature offers convenience of consolidating both media and smart home devices within the home, simplifying the method to control them through one central device to make life easier." Strategy Analytics, Inc. provides the competitive edge with advisory services, consulting and actionable market intelligence for emerging technology, mobile and wireless, digital consumer and automotive electronics companies. With offices in North America, Europe and Asia, Strategy Analytics delivers insights for enterprise success. www.StrategyAnalytics.com. Analyzing UX innovation opportunities in wireless, smart home, and other emerging technologies, UXS forms part of the User Experience Innovation Practice (UXIP) at Strategy Analytics. Focusing on user behaviors, motivations and interests across multiple consumer verticals, UXIP helps clients meet consumer needs, develop usable solutions and deliver compelling user experiences through both syndicated and proprietary research capabilities. With our extensive expertise in large-scale survey work, in-depth interviews, focus groups and observational sessions, UXIP's research methodologies allow strategic user-centric analysis on the potential for new technologies. Providing actionable insight, go-to-market strategies and business recommendations, UXIP is a leading supplier of consumer knowledge to the technology industry. Click here for more information.


Soleimani M.,University of Cincinnati | Soleimani M.,Research Services
Kidney International | Year: 2015

Insulin resistance is associated with hypertension. Nakamura et al. demonstrate in rodents and humans with insulin resistance that while the stimulatory effect of insulin on glucose uptake in adipocytes, mediated via insulin receptor substrate 1 (IRS1), was severely diminished, its effect on salt reabsorption in the kidney proximal tubule, mediated via IRS2, was preserved. Compensatory hyperinsulinemia in individuals with insulin resistance may enhance salt absorption in the proximal tubule, resulting in a state of salt overload and hypertension. © 2014 International Society of Nephrology.


Autonomic imbalances including parasympathetic withdrawal and sympathetic overactivity are cardinal features of heart failure regardless of etiology; however, mechanisms underlying these imbalances remain unknown. Animal model studies of heart and visceral organ hypertrophy predict that nerve growth factor levels should be elevated in heart failure; whether this is so in human heart failure, though, remains unclear. We tested the hypotheses that neurons in cardiac ganglia are hypertrophied in human, canine, and rat heart failure and that nerve growth factor, which we hypothesize is elevated in the failing heart, contributes to this neuronal hypertrophy. Somal morphology of neurons from human (579.54±14.34 versus 327.45±9.17 μm(2); P<0.01) and canine hearts (767.80±18.37 versus 650.23±9.84 μm(2); P<0.01) failing secondary to ischemia and neurons from spontaneously hypertensive rat hearts (327.98±3.15 versus 271.29±2.79 μm(2); P<0.01) failing secondary to hypertension reveal significant hypertrophy of neurons in cardiac ganglia compared with controls. Western blot analysis shows that nerve growth factor levels in the explanted, failing human heart are 250% greater than levels in healthy donor hearts. Neurons from cardiac ganglia cultured with nerve growth factor are significantly larger and have greater dendritic arborization than neurons in control cultures. Hypertrophied neurons are significantly less excitable than smaller ones; thus, hypertrophy of vagal postganglionic neurons in cardiac ganglia would help to explain the parasympathetic withdrawal that accompanies heart failure. Furthermore, our observations suggest that nerve growth factor, which is elevated in the failing human heart, causes hypertrophy of neurons in cardiac ganglia.

Loading Research Services collaborators
Loading Research Services collaborators